OtherClinical Investigations

PET with O-(2-18F-Fluoroethyl)-l-Tyrosine in Peripheral Tumors: First Clinical Results

Dirk Pauleit, Gabriele Stoffels, Winfried Schaden, Kurt Hamacher, Dagmar Bauer, Lutz Tellmann, Hans Herzog, Stefan Bröer, Heinz H. Coenen and Karl-Josef Langen
Journal of Nuclear Medicine March 2005, 46 (3) 411-416;

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    18F-FDG PET (A) and 18F-FET PET (B) of 81-y-old man (patient 2) with high-grade lymphoma (non-Hodgkin’s lymphoma). 18F-FDG shows high uptake in multiple lymph nodes, whereas 18F-FET uptake is negative in all lymph nodes.

  • FIGURE 2.
    FIGURE 2.

    18F-FDG PET (A) and 18F-FET PET (B) of 63-y-old man (patient 32) with head-neck carcinoma (squamous cell carcinoma). Primary tumor and lymph node metastases are positive for both 18F-FDG and 18F-FET.

  • FIGURE 3.
    FIGURE 3.

    18F-FDG PET (A) and 18F-FET PET (B) of 61-y-old man with cancer of tongue (squamous cell carcinoma). Increased 18F-FDG uptake was noted in tumor (large arrow), and additional uptake was demonstrated in inflammatory tissues (small arrows). Increased 18F-FET uptake was noted only in tumor (large arrow).

Tables

  • TABLE 1

    Patient Data, Histologic Diagnosis, and Staging by 18F-FDG PET and 18F-FET PET

    PatientAge (y)SexPrimary tumorHistologic diagnosisConfirmationPretreatment18F-FDG staging*No. of lesions18F-FET staging*No. of lesions
    145FLymphomaHG NHLSurgeryChemotherapyII5(−)0
    281MLymphomaHG NHLBiopsyChemotherapyIV>5(−)0
    341MLymphomaLG NHLBiopsyChemotherapyI1(−)0
    439FLymphomaLG NHLBiopsyChemotherapyIV>5(−)0
    548FColorectalAdenoca.SurgeryChemotherapyT(−) N0, M1>5T(−) N0, M00
    667MColorectalAdenoca.BiopsyNoneT(+) N0, M01T(−) N0, M00
    759MColorectalAdenoca.SurgerySurgery/chemotherapyT(−) N0, M12T(−) N0, M00
    876MColorectalAdenoca.SurgerySurgeryT(+) N0, M1>5T(−) N0, M00
    950MColorectalAdenoca.SurgerySurgery/chemotherapyT(−) N0, M13T(−) N0, M00
    1077MColorectalAdenoca.SurgerySurgery/chemotherapyT(−) N0, M11T(−) N0, M00
    1148MColorectalAdenoca.SurgerySurgery/chemotherapyT(−) N0, M12T(−) N0, M00
    1269FPancreaticAdenoca.SurgerySurgery/chemotherapyT(−) N0, M12T(−) N0, M00
    1354MPancreaticAdenoca.SurgeryNoneT(+) N0, M01T(−) N0, M00
    1456FPancreaticAdenoca.BiopsyChemotherapyT(+) N0, M01T(−) N0, M00
    1562MPancreaticAdenoca.BiopsyNoneT(+) N1, M1>5T(−) N0, M00
    1657MPancreaticAdenoca.BiopsyNoneT(+) N1, M1>5T(−) N0, M00
    1776MPancreaticAdenoca.SurgeryNoneT(+) N0, M01T(−) N0, M00
    1869MLungSCCBiopsyNoneT(+) N1, M1>5T(+) N1, M1>5
    1972FLungSCCBiopsyNoneT(+) N1, M1>5T(+) N1, M1>5
    2069MLungMixed CCBiopsyNoneT(+) N0, M13T(−) N0, M00
    2152FOvarianAdenoca.BiopsyNoneT(−) N1, M1>5T(−) N0, M00
    2246FOvarianAdenoca.SurgerySurgeryT(−) N0, M14T(−) N0, M00
    2363FOvarianAdenoca.SurgerySurgery/chemotherapyT(−) N1, M1>5T(−) N0, M00
    2481MProstaticAdenoca.BiopsyAntiandrogenT(+) N1, M1>5T(−) N0, M00
    2576MProstaticAdenoca.BiopsyAntiandrogenT(−) N0, M11T(−) N0, M00
    2676FBreastIDCSurgeryNoneT(+) N3, M1>5T(−) N0, M00
    2730FBreastIDCBiopsyNoneT(+) N3, M03T(+) N3, M03
    2865FBreastIDCBiopsyNoneT(+) N1, M02T(+) N1, M02
    2965FBreastIDCBiopsyNoneT(+) N1, M02T(+) N1, M02
    3047MHead-neckSCCSurgeryNoneT(+) N2c, M0>5T(+) N2c, M0>5
    3141MHead-neckSCCSurgeryNoneT(+) N0, M13T(+) N0, M01
    3263MHead-neckSCCSurgeryNoneT(+) N2c, M0>5T(+) N2c, M03
    3368MHead-neckSCCSurgerySurgeryT(+) N0, M01T(+) N0, M01
    3473MHead-neckSCCSurgerySurgeryT(+) N0, M12T(+) N0, M01
    3573MHead-neckAdenoca.SurgeryNoneT(−) N0, M00T(−) N0, M00
    3659MHead-neckSCCSurgeryNoneT(+) N1, M02T(+) M0, M01
    3761MHead-neckSCCBiopsyNoneT(+) N1, M13T(+) N0, M01
    3873FHead-neckSCCBiopsyNoneT(+) N1, M14T(+) N0, M01

    • ↵* Clinical staging was done according to International Union Against Cancer with modification of T status as follows: T(+) = tumor present; T(−) = tumor absent. HG NHL = high-grade non-Hodgkin’s lymphoma; LG NHL = low-grade non-Hodgkin’s lymphoma; adenoca. = adenocarcinoma; SCC = squamous cell carcinoma; mixed CC = mixed-cell carcinoma; IDC = infiltrating duct carcinoma of breast.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles